KRAS and MSS

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
SilverWedding
Posts: 71
Joined: Sat May 18, 2019 5:54 am
Facebook Username: Cynthia Harding Marshall

KRAS and MSS

Postby SilverWedding » Wed Oct 30, 2019 10:09 pm

Everything I read says that this is a bad combo with a worse survival rate.

1. Are there any KRAS/MSS success stories to give hope?

2. Also, given this new finding, should we move out of our local can we Center and into the care of a higher level one?

3. FOLFOX starts next week. I hope that sounds right.

We need good news. I love my husband so much, and I hate this.

Thank you,
Cynthia
DH, 56, Sigmoid & rectum
Adenocarcinoma 2cm
 G2: Moderately differentiated
T3N2aM0
Stage IIIb
LN 6/22
5/19 Baseline CEA value - 18.9
Lymphovascular invasion (LVI): present
Perineural invasion (PNI): not identified
Surgical margins: proximal -negative; distal - negative 1.5cm; circumferential - negative 1mm)
MSI status: Waiting‬
Lynch status: ?
KRAS/BRAF: ?
Open Restorative Proctectomy, J-Pouch Coloanal Anastomosis, Loop Ileo w/Appendectomy
Neo-adjuvant Xeloda/radiation
Adjuvant Chemo: to begin 11/19

AlexandraZ
Posts: 178
Joined: Fri Aug 23, 2019 8:25 am

Re: KRAS and MSS

Postby AlexandraZ » Thu Oct 31, 2019 12:27 am

Isn't your husband stage III? I might be wrong, but I really don't think it makes that much of a difference in that case. If you want, you can google Stacy Hurt and read her story. She was a stage 4B patient with KRAS mutation and MSS and she's been NED for years.

For what it's worth, I'd trade my boyfriend's stage 4B for a Stage III with KRAS mutation any day!
Boyfriend 28yo dx February 2019, CEA 70,480
Stage 4 CRC with multiple mets to liver & lungs
KRAS, NRAS, BRAF wild type, MSS
12x FOLFIRI + Vectibix
September 2019 CEA 210, 60% reduction in size, chemo break!

fumaros
Posts: 273
Joined: Sat Jul 02, 2016 10:26 pm
Location: Syracuse, NY
Contact:

Re: KRAS and MSS

Postby fumaros » Thu Oct 31, 2019 8:47 am

You need to stay hopeful. Many brilliant scientist are working on targeting KRAS mutations, and some pharamceutical company have drugs currently under clinical trial with positive results. You can read this article (https://www.fiercebiotech.com/research/ ... ers-clinic).

Stay as healthy as one can for as long they can, and the arc of progress will eventually find a drug that will work. Even on current treatment regimens, colon cancer patients are living longer than ever before.
Diagnosed 4/8/16, age 29
Colectomy 4/20/16
Stage III, T4bN1 Tumor 7x6.5x2. Muscinous Adenocarcinoma with SRC features
2/16 lymph nodes
Stage IV, Peri mets 5/2019
CEA 4/14/16 - 16.8
CEA 6/2/16 - 1.9
CEA 6/17/16 - 0.87, 7/16 - 1.33, 12/16 - 1.14, 4/17 - 0.6, 7/17 - 0.5, 10/17 - 0.9, 3/19 -5.8, 4/19 -10
FOLFOX began 6/24/16 - 11/25/16, FOLFIRI - 5/10/19
10 round FOLFOX, 2 round 5-FU & Leucovorin, 1 round FOLFIRI
MRI & CT 8/16 - NED, CT 12/16 - 10/17 - NED

claudine
Posts: 809
Joined: Tue Mar 12, 2019 2:41 pm
Location: Montana

Re: KRAS and MSS

Postby claudine » Thu Oct 31, 2019 9:38 am

Yes! Fumaros said it all. Cancer research is moving by leaps and bounds... And like Alexandraz noted, your husband is stage 3. I understand what a shock the diagnosis is (went through that) but try to stay positive XXX
Wife of Dx 04/18 (51 yo). MSS, KRAS G12A, no primary

Tumors: L4 04/18; left adrenal gland & small lung nodules 03/19
rectum 02/22 (pT3 pN0 stage 2A); L3 09/22

Surgeries: intestinal resect. 05/18 (no cancer - Crohn's); adrenalectomy 02/20
L3-L4-L5 fusion and corpectomy 05/20; LAR 04/22; ileo reversal 09/22
L2-L3 fusion and corpectomy 09/22

Treatments: EBRT 04/18; SBRT 02/19; Failed adjuvant Xelox ; Folfiri/Avastin 03/19 - 01/20
adjuvant chemorad (Xeloda) 06/22; SBRT 11/22; Xeloda/Avastin since 01/24

claudine
Posts: 809
Joined: Tue Mar 12, 2019 2:41 pm
Location: Montana

Re: KRAS and MSS

Postby claudine » Thu Oct 31, 2019 9:56 am

Also thanks for the link, Fumaros. My husband is G12A, which apparently is only 6% of KRAS mutations, so anything that targets KRAS in general is good news! I guess with his absence of primary and relatively uncommon mets, he just can't do anything like the rest of the world :roll:
Wife of Dx 04/18 (51 yo). MSS, KRAS G12A, no primary

Tumors: L4 04/18; left adrenal gland & small lung nodules 03/19
rectum 02/22 (pT3 pN0 stage 2A); L3 09/22

Surgeries: intestinal resect. 05/18 (no cancer - Crohn's); adrenalectomy 02/20
L3-L4-L5 fusion and corpectomy 05/20; LAR 04/22; ileo reversal 09/22
L2-L3 fusion and corpectomy 09/22

Treatments: EBRT 04/18; SBRT 02/19; Failed adjuvant Xelox ; Folfiri/Avastin 03/19 - 01/20
adjuvant chemorad (Xeloda) 06/22; SBRT 11/22; Xeloda/Avastin since 01/24

NHMike
Posts: 2555
Joined: Fri Jul 21, 2017 3:43 am

Re: KRAS and MSS

Postby NHMike » Thu Oct 31, 2019 12:26 pm

I'm KRAS G12D, probably the most common mutation in Colorectal Cancer. Stage is 3B, same as your husband. I was diagnosed 2.5 years ago and am still around. I'm currently in the state of No Evidence of Disease. Survival stats are 71% (5-year) but this has improved considerably over the past ten years and, obviously, the number is five years old.
6/17: ER rectal bleeding; Colonoscopy
7/17: 3B rectal. T3N1bM0. 5.2 4.5 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/17-9/17: Xeloda radiation
7/5: CEA 2.7; 8/16: 1.9; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8; 5/1 2.8; 5/29 3.2; 7/13 4.5; 8/9 2.8, 2/12 1.2
MSS, KRAS G12D
10/17: 2.7 2.2 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/17: LAR, Temp Ileostomy, Path Complete Response
CapeOx (8) 12/17-6/18
7/18: Reversal, Port Removal
2/19: Clean CT

User avatar
SilverWedding
Posts: 71
Joined: Sat May 18, 2019 5:54 am
Facebook Username: Cynthia Harding Marshall

Re: KRAS and MSS

Postby SilverWedding » Thu Oct 31, 2019 1:23 pm

Everyone - Thank you for giving me hope and putting things into perspective.

It’s just so upsetting, and it seems we keep losing ground. Your advice and success stories are a big key to my optimism. Thank you.

Cynthia
DH, 56, Sigmoid & rectum
Adenocarcinoma 2cm
 G2: Moderately differentiated
T3N2aM0
Stage IIIb
LN 6/22
5/19 Baseline CEA value - 18.9
Lymphovascular invasion (LVI): present
Perineural invasion (PNI): not identified
Surgical margins: proximal -negative; distal - negative 1.5cm; circumferential - negative 1mm)
MSI status: Waiting‬
Lynch status: ?
KRAS/BRAF: ?
Open Restorative Proctectomy, J-Pouch Coloanal Anastomosis, Loop Ileo w/Appendectomy
Neo-adjuvant Xeloda/radiation
Adjuvant Chemo: to begin 11/19

User avatar
Jacques
Posts: 678
Joined: Sun Dec 28, 2014 10:38 am
Location: Occitanie

Re: KRAS and MSS

Postby Jacques » Thu Oct 31, 2019 2:35 pm

SilverWedding wrote:...
2. Also, given this new finding, ...
...

I don't understand... How could this possibly be a "new finding" on October 31 when you said four weeks ago that you just received the "full report"?
On October 1, SilverWedding wrote:... I was able to get the full report and have updated my signature...

Also, you claim that you updated your signature, but your current signature does not contain any of this information on MSI status, or KRAS/BRAF mutations.

This doesn't make any sense to me. Can you explain? What was the date of the specimen they used for these biomarker tests, and what was the date when you actually received this "new finding"?

Thank you.

    Out-of-date signature:
    DH, 56, Sigmoid & rectum
    Adenocarcinoma 2cm
 G2: Moderately differentiated
    T3N2aM0
    Stage IIIb
    LN 6/22
    5/19 Baseline CEA value - 18.9
    Lymphovascular invasion (LVI): present
    Perineural invasion (PNI): not identified
    Surgical margins: proximal -negative; distal - negative 1.5cm; circumferential - negative 1mm)
    MSI status: Waiting‬
    Lynch status: ?
    KRAS/BRAF: ?
    Open Restorative Proctectomy, J-Pouch Coloanal Anastomosis, Loop Ileo w/Appendectomy
    Neo-adjuvant Xeloda/radiation
    Adjuvant Chemo: to begin 11/19


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: No registered users and 35 guests